ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,036.47
-0.69%
US Tech 100
16,927.20
-0.78%
Dow Jones
37,994.92
-1.21%
Brent Oil
88.06
0.96%
Bitcoin
64,637.20
0.55%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Personalis Inc (PSNL) Quote

Personalis Inc

Personalis Inc (PSNL)

Persimmon PLC
Persimmon PLC
Persimmon PLC
1.23
-0.07
( -5.38% )
Updated: 14:41:23
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.23
Bid
1.24
Ask
1.25
Volume
116,032
1.18 Day's Range 1.26
0.8906 52 Week Range 2.60
Market Cap
63.635M
Previous Close
1.30
Open
1.25
Last Trade
1849
@
1.23
Last Trade Time
14:41:23
Financial Volume
$ 143,310
VWAP
1.2351
Average Volume (3m)
337,605
Shares Outstanding
50,503,889
Dividend Yield
-
PE Ratio
-0.59
Earnings Per Share (EPS)
-2.14
Revenue
73.48M
Net Profit
-108.3M

About Personalis Inc

Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.personalis.com
Headquarters
Dover, Delaware, USA
Founded
1970
Personalis Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker PSNL. The last closing price for Personalis was $1.30. Over the last year, Personalis shares have traded in a share price range of $ 0.8906 to $ 2.60.

Personalis currently has 50,503,889 shares outstanding. The market capitalization of Personalis is $63.63 million. Personalis has a price to earnings ratio (PE ratio) of -0.59.

PSNL Latest News

More News

Personalis to Announce First Quarter 2024 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction...

23 hours ago
Business Wire

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on...

March 28 2024
Business Wire

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®...

March 28 2024
Business Wire

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach Personalis, Inc. (Nasdaq: PSNL), a leader in advanced...

March 26 2024
Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and...

March 19 2024
Business Wire

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided...

February 28 2024
Business Wire

Form 8-K - Current report

February 28 2024
Edgar (US Regulatory)

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28...

February 14 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.010.8196721311481.221.41991.182222111.27945674CS
4-0.25-16.89189189191.481.541.182352281.32777994CS
12-0.13-9.558823529411.361.81.123376051.43757776CS
260.1817.14285714291.052.380.89065112291.46956852CS
52-1.08-46.75324675322.312.60.89063693721.59485978CS
156-22.18-94.745835113223.4128.470.89064434907.67676207CS
260-22.47-94.810126582323.753.460.890649173814.67330062CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BACKIMAC Holdings Inc
$ 7.2564
(108.22%)
4.7M
SGBXSafe and Green Holdings Corporation
$ 0.23
(59.61%)
118.28M
BRFHBarfresh Food Group Inc
$ 1.62
(57.28%)
40.42M
PCSAProcessa Pharmaceuticals Inc
$ 2.45
(51.23%)
69.93M
NUWENewellis Inc
$ 0.374249
(48.45%)
7.37M
EJHE Home Household Service Holdings Ltd
$ 0.788
(-72.92%)
11.3M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2753
(-35.27%)
14.64M
ATNIATN International Inc
$ 18.82
(-34.47%)
289.89k
CYCCCyclacel Pharmaceuticals Inc
$ 1.52
(-33.91%)
3.27M
BNAIBrand Engagement Network Inc
$ 2.62
(-29.76%)
198.73k
SQQQProShares UltraPro Short QQQ
$ 12.0833
(2.31%)
129.79M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
118.28M
ACONAclarion Inc
$ 0.4065
(41.15%)
108.01M
TSLATesla Inc
$ 166.30
(2.57%)
89.37M
METAMeta Platforms Inc
$ 438.88
(-11.07%)
70.3M

PSNL Discussion

View Posts
glenn1919 glenn1919 2 months ago
PSNL..................................https://stockcharts.com/h-sc/ui?s=PSNL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 months ago
PSNL new 52=week low
👍️0
ottoman ottoman 6 months ago
Damn, is Cathy dumping? This turd sandwich never taste any better the more I nibble.
👍️0
Monksdream Monksdream 6 months ago
PSNL new 52 week low
👍️0
Invest-in-America Invest-in-America 1 year ago
PSNL: Got some nice REVS/INCOME news late yesterday, Peeps --- could get a little run-up today.
https://pulse2.com/why-the-personalis-stock-increased-over-10-psnl/
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020.

"The VA MVP is the largest whole genome sequencing project in the United States and this is a significant milestone for both the program and for Personalis," said John West, Chief Executive Officer. "Population-scale sequencing projects of this nature represent a cornerstone in our effort to accelerate the advancement of precision medicine across a wide range of disease areas. With our sizable investments in the technology and infrastructure, necessary to win and execute these projects, Personalis sees population genomics and health as key priorities for our company. We congratulate the VA MVP for their visionary leadership and note that VA scientists now list over 50 peer reviewed publications from the Program."

https://finance.yahoo.com/news/personalis-announces-delivery-100-000th-210700535.html
👍️0
JGrumby JGrumby 5 years ago
Hearing that Monday PSNL will start to get Wall street research reports. Look at PSNL vs GH and NVTA etc
👍️0
JGrumby JGrumby 5 years ago
Nice day after the post IPO sell off.
👍️0

Your Recent History

NASDAQ
PSNL
Personalis
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved